Paragard IUD Cases in 2026: Intake and Marketing Strategy for Plaintiff Firms

Paragard IUD: What Plaintiff Firms Need to Know Before Spending a Dollar on Acquisition

Paragard mass tort marketing remains one of the more cost-efficient acquisition opportunities in the current plaintiff landscape, driven by a confirmed MDL, a qualifying claimant pool estimated in the tens of thousands, and case costs that have not yet spiked ahead of resolution. The litigation has genuine scientific footing, device fracture on removal is well-documented, but bellwether trials and settlement signals are still developing. Firms that build inventory now, before resolution activity tightens the market, are positioned to capture the strongest return on acquisition spend.

The Litigation Landscape and What It Means for Case Value Timing

The Paragard MDL (MDL 2974) is consolidated in the Northern District of Georgia before Judge Leigh Martin May. As of this writing, the MDL has grown to several thousand active cases, with plaintiff filings continuing at a moderate pace. The litigation centers on a straightforward defect theory: the copper T-shaped IUD fractures during removal, leaving broken arms or fragments inside the patient. The mechanism is documented, the FDA has received thousands of adverse event reports, and the science supporting the defect claim is credible enough that Daubert risk, while real in any device case, is not the primary threat to long-term value here.

That said, the MDL has not produced bellwether verdicts. Discovery is ongoing. The parties have moved through early case management but the litigation has not yet hit the inflection point that typically triggers serious global settlement conversations. The TortIntel Jacob Score for Paragard sits at 52 out of 100, with Verdicts rated Weak and Timeline rated Developing. That score reflects the reality: this is a pre-bellwether device tort with moderate science and a developing momentum profile. It is not a mature tort with a funded settlement grid. It is also not a speculative long shot with shaky liability.

For a plaintiff firm, what that means practically is this: cases you sign today will likely sit for 18 to 36 months before any resolution event. Firms with the capital and docket management to hold inventory through that window stand to benefit from acquiring at current prices. Firms that need 12-month case velocity should look elsewhere or build a mixed portfolio. The eventual resolution, when it comes, will be driven by bellwether results, and the first trials will shape settlement values substantially. Getting positioned before those results is the acquisition play.

The Claimant Pool and Demand Side

Paragard has been on the U.S. market for decades. Millions of devices have been placed. The subset of women who experienced a fractured device during removal represents the qualified claimant pool, and while exact numbers are difficult to pin down, adverse event data and litigation trends suggest the addressable pool of unrepresented potential plaintiffs still numbers in the tens of thousands nationally.

Saturation is moderate, not extreme. This is not a tort like Camp Lejeune or 3M Earplugs where national advertising has run for years at nine-figure aggregate spend. Paragard advertising has been more measured, which means a meaningful portion of the potential claimant population has not yet been reached by firm outreach. That creates a real window for firms willing to run deliberate, well-targeted campaigns.

Geographically, the qualifying population mirrors the national distribution of IUD users, skewing toward metro areas and regions with higher rates of long-acting reversible contraceptive adoption. There is no single geographic concentration the way you see in some environmental or occupational torts. That means digital channels, particularly Facebook and Instagram, are more efficient than regional broadcast for this audience, because you can target by age and interest signals nationally without wasting budget on markets with no density advantage.

Paragard Mass Tort Marketing: Advertising Economics for Plaintiff Firms

Paragard mass tort marketing economics are currently attractive relative to more mature torts. Because the tort has not hit peak advertiser competition, cost-per-lead (CPL) on paid social is running in a range that makes the math work for firms with realistic case value expectations. Rough benchmarks from campaigns we have run and monitored: CPL on Facebook and Instagram tends to fall between $80 and $180 for raw leads, depending on creative quality, targeting precision, and landing page conversion. Cost per signed retainer, after intake screening, typically runs $600 to $1,400 at current market saturation levels.

Those numbers will move. As bellwether dates firm up and settlement speculation increases, more firms will enter the advertising market, CPLs will rise, and the cost-per-signed-case will follow. Firms buying now are buying at a discount to where this market will likely be in 18 months if the MDL continues to develop favorably.

Facebook and Instagram remain the dominant channels for this tort because the qualifying population (women, typically between 25 and 45, who had a Paragard IUD removed) is reachable through Meta's behavioral and interest targeting at scale. Creative angles that convert focus on the removal experience specifically, emphasizing the documented fracture risk and the connection between that event and the legal landscape, without veering into consumer-directed medical advice. The creative job is to generate recognition and a response from people who lived through the experience. Short-form video outperforms static at this stage of the tort's lifecycle. Advertorial-style landing pages that explain the litigation context tend to produce better qualified leads than generic "case review" pages.

Search (Google and Bing) is a secondary channel here. Search volume for Paragard-related legal queries exists but is lower than for higher-profile torts, so search economics are less competitive but also lower volume. It works as a complement to paid social, not a primary driver.

Intake, Qualification, and Making Signed Cases Stick

From the firm's side, qualifying a Paragard case comes down to a few hard criteria. The potential plaintiff must have had a Paragard IUD, it must have fractured or broken during removal (or during attempted removal), and there must be medical documentation of the device, the removal procedure, and ideally the complication. Cases with strong documentation, treating physician records confirming the fracture and any resulting injury or procedure, are the cases worth holding. Cases with weak documentation or where the claimant cannot clearly confirm the fracture occurred are higher risk and lower value.

Intake flow should prioritize speed on the initial contact (response within minutes from web lead to call dramatically improves conversion) and document collection early in the retainer process. Firms that chase signatures and defer document collection often find their retained inventory is softer than expected when they go back to verify. Build the verification step into the intake workflow before the retainer is countersigned, not after.

Co-counsel arrangements are common in this tort. Firms that are not litigating the MDL directly typically refer into one of the lead or liaison firms. If you are acquiring cases for referral, your economics depend on the referral fee structure, so model your cost-per-signed-case against the expected fee share before committing a budget.

How MTAA Approaches This Tort

At Mass Tort Ad Agency, we have managed over $250 million in Facebook ad spend across 600-plus plaintiff firms and more than 100 torts. Paragard is a tort we approach with the same transparent cost-plus structure we use across every campaign: firms pay actual ad spend plus a 15% management fee, no markup on media, no hidden margins. That model matters on a developing tort like Paragard because firms need to see exactly what their acquisition dollars are doing and adjust based on real data, not inflated reporting.

For a tort at Paragard's stage, we typically recommend a measured entry: set a monthly test budget, run two or three creative variations, and optimize toward cost-per-qualified-lead before scaling. Scaling before the creative and targeting are proven is how firms burn capital on developing torts. Patience in the ramp-up phase, followed by aggressive scaling when the economics are confirmed, is the right sequence here.

The AI angle is increasingly relevant too. Firms using AI-assisted intake tools, whether for initial lead response, document request automation, or case scoring, are seeing meaningfully better conversion rates from lead to signed retainer. If you are building or refining your intake stack alongside a Paragard campaign, it is worth reading up on how these tools are being applied in plaintiff firms right now. "A Lawyer's Guide to AI" covers the practical side of that without the hype.

The Bottom Line on Paragard as a Case Acquisition Play

Paragard is a legitimate mid-tier tort with credible science, a functioning MDL, and a claimant population that has not been exhausted by advertising saturation. The timeline to resolution is longer than some firms prefer, and the absence of verdicts or settlement signals means you are buying potential rather than certainty. But that is also exactly why acquisition costs are manageable right now. Paragard mass tort marketing done with discipline, right creative, right channels, verified intake, and a clear-eyed view of the hold period, is a reasonable portfolio addition for firms that can carry inventory through the MDL's next phase. Firms that wait for the first bellwether result to validate the investment will pay significantly more per case and sign fewer of them. Paragard mass tort marketing rewards early movers who do the work to qualify cases properly. That has been true of nearly every device tort we have worked, and Paragard is following the same pattern. If you are evaluating budget allocation for the next 12 months, this tort deserves a serious look before the market catches up to where the litigation is heading.